SURYAPHARM

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors, in its meeting held on February 3, 2015 have approved and taken on record the Report of Statutory Auditors of the Company on the financial statements of the Company as on and for the year ended March 31, 2014.

Surya Pharmaceutical Limited had informed the Exchange regarding meeting of the Board of Directors of the Company scheduled to be held on May 30, 2014 to consider and approve Audited Financial Results i.e. Balance Sheet, Profit & Loss Account, Schedules and Notes thereon for the year ended March 31, 2014 of the Company. The Company has now inform the Exchange that the said meeting has been adjourned for the want of quorum as two of the three Directors of the Company, i.e. Mr. Rajiv Goyal and Mrs. Alka Goyal are out of India and were not able to attend the said meeting.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 10, 2013, have appointed Mr. Jasvinder Singh as Independent Additional Director of the Company.

Surya Pharmaceutical Limited has informed the Exchange regarding outcome of the Board Meeting held on August 14, 2013.

Surya Pharmaceutical Limited has informed the Exchange regarding a Outcome of Board Meeting held on May 30, 2013.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 14, 2013 has transacted the following: (1). Mr. Subhash Chander Marwaha has been appointed as Nominee Director-SBl w.e.f. January 23, 2013.(2). Further in continuation of the Company's previous communication with respect to decision of State Bank of India (the lead bank) for restructuring of the Company's debt, it is hereby informed that the Corporate Debt Restructuring empowered group(CDR-EG) has approved the restructuring package and taken on record in the Board o

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company held on July 07, 2012 approved the following: (1) The Board has appointed Mr. Bharat Bhushan Jain as Company Secretary & Compliance officer of the Company in place of Mrs. Sugandha Kukreja w.e.f. June 16, 2012.(2) Further, Mr. Sanjay Kumar Suroya, Nominee Director of IDBI has resigned from the Directorship of the Company w.e.f. July 05, 2012.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 11, 2012, Mr . Devinder Pal has resigned from the directorship of the Company. The Board has appointed Mr. Sanjay S. kumar as Nominee Director-IDBI Bank in place of Mr. Ashwani kumar Agarwal.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 13, 2011 considered the following : (1) Dr. M.L. Sharma has resigned from the directorship of the Company w.e.f. July 23, 2011. The Board has appointed Dr. R.K. Gupta as Independent Additional Director of the Company with immediate effect; (2) The Board of Directors of the Company has decided to mobilize funds through Fixed Deposits.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors in their meeting held on October 12, 2010 successfully closed the subscription list of issue of GDR of USD 25 million. The issue has been fully subscribed.

Surya Pharmaceutical Limited has informed the Exchange that the Boards of Directors in their meeting held on October 07, 2010 has decided to issue GDR for USD 25 million and the subscription list for the same has been opened. The subscription list is expected to remain open till October 12, 2010. A meeting of the Board of Directors has been convened to be held on October 12, 2010 to decide on the date of closure of the subscription list.

Surya Pharmaceutical Limited has informed the Exchange that (1) Subject to the approval of the shareholders and other regulatory approvals, if any, the Board has decided to raise upto Rs. 300 crores or equivalent USD from Domestic or International Market by issue of permissible securities for funding its new projects, expansions, diversifications, acquisitions, other business expense and to augment working capital requirements. (2) Subject to the approval of the shareholders and other regulatory approvals, if any, the Board has decided to raise upto 50 million USD through issue of Foreign Curr

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors at its meeting held on May 11, 2010 have considered the following : (1) The Board discussed the future funds requirements of the Company and instead of going ahead with the Rights Issue decided to frame a composite issue and accordingly, the Board constituted a Committee to frame a suitable structure for funds mobilization and seek approval of the shareholders in accordance with Law. (2) Subject to the approval of the shareholders, the Board has decided to increase the Authorized Share Capital from Rs. 50 Crores

Surya Pharmaceutical Limited has informed the Exchange that " The Board of Directors in their meeting held on 29.04.2010 has allotted 47,00,000 zero coupon convertible share warrants to M/s Futuristics Garments Private Limited in terms of Resolution passed in the Extra Ordinary General Meeting of Shareholders of the Company held on 14.03.2009"

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company in their meeting held on January 29, 2009. (1) Subject to the approval of the shareholders, the company has resolved to increase the authorised capital of the Company from Rs.26.00 Crores, divided into 2,60,00,000 Equity Shares of Rs.10/- each to Rs.50.00 Crores, divided into 5,00,00,000 Equity Sahres of Rs.10/- each. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announc

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors at their meeting held on January 28, 2006 have interalia approved the following :-(i) subject to the approval of the shareholders, the Company has resolved to increase the authorised capital of the company from Rs.20.00 Crores, divided into 2,00,00,000 Equity shares of Rs.10.00 each, to Rs.26.00 Crores, divided into 2,60,00,000 Equity Shares of Rs.10.00 each. (ii) Subject to the approval of the shareholders the Company has resolved to amend Memorandum of Association and Articles of Association to give effect to

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors in their meeting held on July 05, 2005 have taken the following decisions: 1) Subject to the approval of the shareholders, the company has resolved to increase the authorised capital of the company from Rs.15.00 Crores, divided into 1,50,00,000 Equity Shares of Rs.10.00 each, to Rs.20.00 Crores divided into 2,00,00,000 Equity Shares of Rs.10.00 each. 2) Subject to the approval of the shareholders, the Company has resolved to amend Memorandum of Association and Article of Association to give effect to the increas

Surya Pharmaceutical Limited has informed the Exchange that the company convened a meeting of the BODs on December 23,2004.The said meeting was adjourned to be held on December 24,2004.The following decisions were taken at the aforesaid meeting:1)Subject to the approval of shareholders, the company has resolved to increase the authorised capital of the company from Rs.11 Crores, divided into 1,10,00,000 Equity Shares of Rs.10.00 each, to Rs.15 Crores, divided into 1,50,00,000 Equity Shares of Rs.10.00 each.2)Subject to the approval of the shareholders, the company has resolved to amend the Mem

Surya Pharmaceutical Limited has informed the Exchange that the BoD's of the company in their meeting held on September 29, 2004, have decided to mobilize the funds through Fixed Deposits.